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INTRODUCTION  
―Post mastectomy seroma remains an unresolved quandary as the risk factors 
for its formation have still not been identified. Seromas of the axillary space 
following breast surgery can lead to significant morbidity and delay in the 
initiation of adjuvant therapy. Various techniques and their modifications have 
been practiced and published in English literature, but there seems to be no 
consensus. In this article, all aspects of seroma formation from pathogenesis to 
prevention including drug therapies have been discussed.‖ 
            ― Seroma is a collection of serous fluid in the dead space of post-
mastectomy skin flap, axilla or breast following modified radical mastectomy 
(MRM) or breast conserving surgery (BCS) and is the commonest early sequel. 
However, there is inconsistency in the definition of seroma across published 
works. This presumed complication, albeit usually of minor consequence, may 
prolong recovery, length of hospital stay and over stretch health budget. The 
reported incidence of seroma formation varies widely between 15 and 18% . 
There are several factors implicated in seroma formation like the extent of 
lymph node clearance, number of positive nodes, the use of postoperative 
radiation and whether intraoperative lymphatic channel ligation was done or 
not, but opinion differs as to their individual role in its pathogenesis. The main 
pathophysiology of seroma is still poorly understood and remains controversial. 
The optimal ways to reduce the incidence of seroma formation are unknown.‖ 
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This is a prospective study conducted at Rajiv Gandhi Government General 
Hospital, Chennai in patients admitted to all general surgical units over a one 
year period. All patients were managed according to standard guidelines. The 
role of inj methyl prednisolone against seroma formation in post MRM patients 
were studied. The distribution of age and other factors determining the seroma 
formation were also studied. 
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AIMS AND OBJECTIVES  
  
1. Study to establish the prophylactic effects of inj Methyl prednisolone 
against seroma formation .  
2. Study of factors determining seroma formation.  
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REVIEW OF LITERATURE 
―Seroma formation is one of the troublesome complication  after 
MRM.The pathogenesis of seroma has not been fully elucidated. Seroma is 
formed by acute inflammatory exudates in response to surgical trauma and 
acute phase of wound healing . Oertli et al believed that the fibrinolytic 
activity contribute to seroma formation. Petrek et al in a prospective 
randomized trial showed that the most significant influencing factors in the 
causation of seroma were the number and extent of axillary lymph node 
involvement. However, Gonzalez et al. and Hashemi et al. reported that 
the only statistically significant factor influencing the incidence of seroma 
formation was the type of surgery. They reported higher seroma rate in 
MRM than following wide local excision and axillary dissection (BCS). 
Factors such as age of the patient, obesity, tumor size and neoadjuvant 
therapy did not influence the incidence of seroma formation in the three 
mentioned studies. Extensive dissection in mastectomy and axillary 
lymphadenectomy damages several blood vessels and lymphatics and the 
subsequent oozing of blood and lymphatic fluid from a large surface area 
when compared with breast conserving surgery leads to seroma .‖ 
         ― Seroma accumulation elevates the flaps from the chest wall and 
axilla there by hampering their adherence to the tissue bed. It thus can lead 
to significant morbidity such as wound hematoma, delayed wound healing, 
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wound infection, wound dehiscence, prolonged hospitalization, delayed 
recovery and initiation of adjuvant therapy.‖ 
Prevention and Reduction of Seroma Formation: 
There are several techniques in practice that have been reported to prevent 
or reduce seroma formation, but no single method has been shown to be 
consistently and reliably effective. They can be discussed as  surgical 
techniques, (2) the use of sealants and sclerotherapy, (3) compression 
dressing, (4) the use of drains, (5) shoulder exercise (delayed vs early) and 
(6) the role of Octreotide 
                                              FEMALE BREAST 
―The female breast has always been a symbol of beauty,fertility and 
femininity. In disease, however, it has challenged physicians since 
antiquity. Surgery, which ruled the roost for cancer therapy, inevitably 
caused disfigurement when the knife was applied to the breast. The history 
of breast cancer is a complex maze of attempts to understand the wily 
nature of this hormone-responsive cancer and the will of physicians to 
conquer it by physical removal (surgery), cell destruction (chemo-
radiotherapy) or targeted therapy to cell receptors (biomodulation). It is 
also a saga of intense exploration to find the tools to enable early 
diagnosis. The story of the domination of surgery over two millennia and 
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its evolution from fatalistic choices to minimal damage is told in the 
succeeding paragraphs. The pathobiological basis of breast cancer that 
changed chirurgical practice from crudity to finesse is woven through the 
narrative.‖ 
Beliefs and Practices Through Antiquity: 
― It is not surprising that written records and illustrations of breast cancer 
date back to antiquity since the location of the organ permitted easy 
identification. The Edwin Smith Surgical Papyrus, dating back to 3,000–
2,500 B.C., and possibly attributable to Imhotep (the Egyptian physician-
architect), provides authentic accounts of breast cancer. A case was 
deemed incurable if the disease was ―cool to touch, bulging and spread all 
over the breast‖. In ancient Greece, a divinity was exhorted to offer relief 
from breast maladies, as evidenced by votive offerings in the shape of 
breasts in Greek temples that housed Asclepius, the god of 
medicine.Carcinoma (karkinoma), scirrhous (hard, Greek skirros) and 
cacoethes (malignant disease, Greek kakoethes) in the medical lexicon 
owe their origins to Hellenistic writings.‖ 
       ― Hippocrates‘ theory in c. 400 B.C. of the imbalance of humours 
(blood, phlegm, and yellow and black bile) as a cause of disease, and his 
classic descriptions of the progressive stages of breast cancer, represent 
early hypotheses on the cause of cancer.Leonides of Alexandria, in 1st 
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century A.D., preserving the Greek traditions, boldly and skillfully 
detailed his approach of incision and cautery. His stipulation of leaving a 
wide margin of excision and only removing tumours of limited extent, 
foreshadows the oncological principles of contemporary surgical 
practice.Galen, attributing breast cancer in A.D. 200 to the accumulation 
of black bile in the blood, concluded that it was a systemic disease.These 
ancient physicians postulated that the cessation of menstruation was 
somehow linked to cancer; in fact it probably had to do with the 
association of cancer with old age. In line with this theory, Galen allowed 
surgical wounds to bleed freely to get rid of the black bile and frowned on 
the use of ligatures. The word ‗crab‘ for cancer was coined by him to 
illustrate the dilated veins radiating from the tumour.‖ 
Surgical Stagnation in the Middle Ages: 
 ―Between 476 and 1,500 A.D. medical progress was inextricably 
intertwined with the emerging religious philosophies. Early Christian 
beliefs favoured faith healing and miracles over surgery, which was 
perceived as barbaric. Islamic emergence revived Greek medicine and, 
through meticulous translations, saved medical knowledge for posterity. 
Avicenna (Ibn Sina, Persia) and Albucasis (Abu Al-Qasim Al-Zahrawi, 
Spain) in the 10th century and Maimonides (Spain) in the 12th century 
were Arab physicians of renown, forming a trio of exemplars who spread 
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medical excellence to the boundaries of the expanding Islamic conquests. 
Albucasis was a strong advocate of the use of cautery in surgery. The use 
of caustic pastes to annihilate the tumour and render it operable, is 
reminiscent of the same logic for using chemotherapy for large breast 
cancers today. Unique instruments to aid in the rapid removal of breast 
tumours were introduced into the surgical armamentarium by Albucasis, 
Henri de Mondeville (‗father‘ of French surgery, 13th century) and Guy de 
Chauliac (France, 14th century).‖ 
Renaissance: A Celebration of emergence of surgery: 
―The 16th to 18th centuries not only bred artistic creativity but proved to 
be the golden age for the emergence of surgery. The craft of surgery was 
unshackled from its previous conjoint status with the barber‘s trade and 
grew on the shoulders of a strong anatomical exploration of the human 
body by Andreas Vesalius in 16th century Belgium. In 18th century 
England and France, respectively, Cooper‘s eponymous ligaments of the 
breast and Sappey‘s subareolar plexus of lymphatics ushered in an era that 
revisited the origins and spread of breast cancer. In the same era, John 
Hunter (the Scottish ‗father‘ of investigative surgery) replaced ‗black bile‘ 
with lymph as the cause of breast cancer. A multitude of theories ranging 
from inspissated milk, trauma, personality type, exposure to air and 
infection were fed into the cauldron of carcinogenesis. The observation of 
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the disease within families was naturally attributed to infection. Amidst 
this chaotic search for the truth, accounts of heroic surgeries from simple 
lumpectomies to radical removal of the pectoralis, enliven medical 
records.These are rendered more vivid and admirable when it is recalled 
that in the absence of anaesthesia, skill and speed were the sole attributes 
of a successful surgeon. It is also a grim reminder that surgery was the 
solitary modality for hope of relief with anecdotal incidences of cure. 
More conservative compatriots used ligatures or lead plates to strangulate 
the tumours, preferring them to the horrors of breast amputation.‖ 
Nineteenth Century: The golden age of surgery 
 ―The surgical discipline rapidly grew on the bedrock of a spate of 
discoveries that rendered it safer with a good outcome for the patient. 
Disinfection and sterilisation and the use of sterile gloves were the first 
landmark events. General anaesthesia revolutionised the surgeon‘s ease 
(and indeed the patient‘s too!). Although in 1818 James Blundell 
attempted blood transfusion in postpartum haemorrhage, safe transfusions 
would be achieved only at the dawn of the 20th century with the discovery 
of blood groups by Karl Landsteiner. Against this background, seminal 
contributions to cancer came from the microscopic identification of normal 
cells and their cancerous brethren all the way from Hooke in 17th century 
England to Müller and Virchow in 19th century Germany. Müller 
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dismissed the humoral theory of the origin of cancer, declaring that 
cancers were composed of living cells and suggesting that metastasis was 
due to spread of these cells. The demonstration that breast cancer spread 
along the lymphatics to the guardian axillary nodes was to form the basis 
of a variety of excision techniques. Unique forms of spread leading to the 
clinical manifestations of carcinoma en cuirasse or peau d‘orange and 
Paget‘s disease would demand alternative ways of approaching treatment.‖  
―The middle years of the 19th century celebrated the newly acquired 
surgical freedom with bold and radical surgeries. The en bloc resections of 
Charles Moore in London, and Kuster and Volkmann in Germany ran a 
parallel course. Axillary lymph node dissections as part of the philosophy 
of extermination were performed in 1882 by William Banks in Liverpool, 
UK. While they may appear particularly mutilating today, they provided a 
unique opportunity to study the disease spread. Breast cancer surgery at 
the turn of the century came to be synonymous with the name of William 
S. Halstead, Professor of Surgery at Johns Hopkins hospital in Baltimore, 
USA. His radical mastectomy (first reported in 1894) with its emphasis on 
removing tissues in one piece to prevent spread and removal of the 
pectoralis major to prevent recurrence, became the undisputed path that 
generations of surgeons trod with diligence.‖ ―The suspected tissue should 
be removed in one piece, (1) lest the wound become infected by the 
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division of tissues invaded by the disease or of lymphatic vessels 
containing cancer cells, and (2) because shreds or pieces of cancerous 
tissue might readily be overlooked in the piecemeal extirpation.‖ 
 These strict rules for non-violation of the tumour area precluded a 
preoperative biopsy to confirm whether the patient had a cancer at all: such 
was the strength of a skilled clinical diagnosis! Another ageold practice 
that came to a close was to leave the excised surgical wound open to 
granulate. The use of ligatures now allowed better wound healing through 
low infection rates. 
 Twentieth Century: Surgery reinvents itself  
―The hormone dependency of breast cancer was initially hypothetical, 
through the observation that the disease was aggressive in younger 
women. Beatson ignited the era of endocrine surgery in 1906—long before 
the discovery of estrogen receptors by Jensen in 1967 and oopherectomy 
and adrenalectomy (to achieve castration) came in vogue. These rather 
drastic methods were gradually overtaken by estrogen receptor 
modulators, luteinising hormone-releasing agonists and aromatase 
inhibitors‖. 
― Halstead‘s legacy was, for a while, preserved by Margottini and Veronesi 
in Milan who additionally removed internal mammary nodes and others 
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who extended the scope of ‗radicality‘ to supraclavicular and mediastinal 
nodes. However, the late 19th and early 20th centuries gradually heralded 
the demise of the adage: big surgeons make big incisions (and hence 
perform big surgeries). Patey and Handley from London and Auchincloss 
Jr. of New York ushered in a movement that ‗modified‘ the radical 
mastectomy and preserved the pectoralis major. Rapid advances in medical 
radiation as a means of killing cancer cells and new forms of 
chemotherapy that did the same, but also achieved medical castration or 
targeted mutated tumour receptors, forced a rethink of cancer management 
strategies. These were coupled with the burgeoning knowledge of the 
biological behaviour of breast cancer and the less-than-guaranteed success 
of surgery alone. Early cancer detection of smaller lesions by 
mammography added a new dimension to surgical management.‖ 
―The clarion call to reorient to limited surgery came from the surgery 
fraternity. Bernard Fisher, Professor of Surgery at the University of 
Pittsburgh, revived Galen‘s ancient belief that breast cancer was a 
systemic disease. Large randomised controlled clinical trials like the 
National Surgical Adjuvant Breast and Bowel Project (NSABP), published 
in 1989, provided scientific support.It is ironic that the disbandment of the 
radical Halstedian approach, the institution of trials and the acceptance of 
neoadjuvant therapy were the brainchildren of a surgeon!‖ 
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 Veronesi from Italy and many others supported the notion of limited 
surgery complemented by adjuvants. Surgery reinvented itself to join 
hands with the other modalities. Since the close of the 20th century breast 
conservation and breast reconstruction—combined, where necessary, with 
sentinel node dissection—have held sway. The removal of only selected 
‗sentinel‘ nodes (those to which the tumour had spread) would relegate the 
swollen lymphoedematous arm, a distressing manifestation of axillary 
lymph node dissections, to the annals of surgical history. 
 Once surgeons lead the revolution towards minimising extirpation, the 
first faltering steps towards restoring cosmesis were taken by Verneuil, a 
French surgeon who transferred autologous tissue from the normal breast 
to the diseased one in 1887.This released the floodgates for a variety of 
innovative autologous and synthetic materials offering a restored shape 
that could even outdo nature‘s original creation. Muscle, myocutaneous 
flaps, lipomas and omentum were natural choices. The transverse rectus 
abdominis myocutaneous flap (TRAM) introduced in 1979 by Holmstrom 
has stood the test of time, undergoing several modifications in its 
evolution.Prosthetic and synthetic options brought industry and commerce 
into the fray: petroleum jelly, glass balls, ivory, rubber, polyvinyl alcohol 
sponge and silicone— the list is ever growing!  
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―Surgical domination over the treatment of breast cancer held sway for the 
millennia, ever since the first recorded medical literature. The hope for a 
cure by the radical removal of a diseased organ was always 
counterbalanced by fascinating and fearsome accounts of surgery sans 
anaesthesia as a physically and psychologically mutilating therapeutic 
option. While nowhere near its nadir, surgery remains at the heart of 
management in a multimodality setting. Instead of annihilation it now 
provides succour to the breast cancer survivor thus balancing cure and 
cosmesis‖. 
Lessons from the History of Surgery in Breast Cancer  
―There are three lessons to be gained from the history of surgery in breast 
cancer. First, to delve into history is to rediscover buried insights: Galen‘s 
perceptive assessment that breast cancer is a systemic disease was echoed 
two millennia later in Fisher‘s 20th century observations. Second, the 
evolution of therapeutic weaponry raises the fortunes of medical 
disciplines (as antisepsis and anaesthesia did for surgery) or minimises 
their supremacy as stand-alone choices for panacea or cure (as 
chemoradiotherapy did for surgery). Third, stooping to conquer is the mark 
of survival in contemporary medical practice. Surgery has won the day by 
adapting and playing a complementary role in modern cancer management 
as a stylised, scientific and patient-friendly craft.‖ 
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EMBRYOLOGY 
―The human breasts develop from the mammary ridges or milk lines 
which result due to thickening of the epidermis which usually appear first 
on the anterior surface of a 5 week old fetus that extends from the axilla to 
the upper and medial aspect of the thigh. These ridges continue to develop 
in the pectoral region and the remaining ridges disappear. The epithelial 
cells proliferate, enlarge and grow downward into the underlying 
mesenchymal tissue. By the end of the fifth month of gestation, 15 to 20 
solid cords can be identified. These cords continue to grow downwards 
and branch, then slowly acquire lumina by hollowing in the last 8 weeks 
of the fetal life.‖  
 
 
 
 
FIG:Mammary Ridge &  Breast Anomalies 
Ref: Taken from Moore‘s anatomy text book.  
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The previously elevated flat surface of the developing nipple 
develops a depression (the mammary pit) into which these lactiferous 
ducts open. At about the time of birth the mammary pit evaginates 
outwards to form the definitive nipple as a result of proliferating 
mesenchyme.  
 
―The earliest stages development of the fetal mammary gland 
appears not to be depends on the steroid hormones, whereas actual 
development of  breast structure after the 15th week is mediated by 
testosterone. In the last few weeks of gestation,  fetal breast is usually 
responsive to placental and maternal steroid hormones and prolactin, that 
induce secretory activity in the fetal mammary ducts. This is the reason 
for  secretion of colostrum immediately after birth and palpable breast bud 
enlargement. But due to disappearance of maternal hormones from infant's 
blood stream, the secretory activity subsides and ceases after birth within a 
month or two. The mammary gland shrinks and returns to an inactive 
state‖.  
 
In males mammary glands remain rudimentary throughout life but in 
most of the females, further breast development  begin only after reaching 
puberty.  
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FIG - Development of mammary glands 
A : 28 days embryo showing mammary crests. B : 6 weeks, showing 
remains of the crests.  
C, D, E, F : successive stages in the development between 12th week and 
birth.  
Ref: Taken from Moore‘s anatomy text book.  
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Female Breast Development & its Endocrine Control  :  
―Breast development commences with  secretion of cyclical 
estrogen and the progesterone secretion at puberty. Estrogen is responsible 
for the differentiation of peri-ductal stroma and growth of the ducts that 
elongate and acquire a thickened epithelium. Growth hormone and gluco-
corticoids also contribute to ductal growth.  
 
Lobules are derived from solid masses of cells that form at the end 
of terminal ducts. Lobulo-alveolar differentiation and the growth during 
this puberty time are stimulated and increased  primarily by insulin, 
progesterone and growth hormone . Though the greatest amount of breast 
FIG - Phases of Human Breast Development :  
Sketches showing progressive stages in the postnatal development of the 
breasts.  
A-Newborn. B-Child. C-Early puberty. D-Late puberty. E- Young adult. F-
Pregnant female.  
Ref: Taken from Moore‘s anatomy text book.  
.  
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glandular differentiation occurs at puberty, the differentiation process 
continues into the second decade and is further enhanced by pregnancy. 
The evolution of breast from childhood to maturity has been divided into 
five phases by Tanner .‖ 
Phase I (age: puberty) : Pre adolescent elevation of the nipple. No 
palpable glandular tissue or areolar pigmentation.  
 
 Phase II (age: 11.1 ± 1.1 yr) : Presence of glandular tissue in the 
sub areolar region of breast. The nipple and breast project as a single 
mound from the chest wall.  
 
Phase III (age: 12.2 ± 1.09 yr) : Increase in the amount of readily 
palpable glandular tissue and enlargement of the breast with increased 
diameter and pigmentation of the areola. The contour of the breast and 
nipple remains in a single plane.  
 
Phase IV (age: 13.1 ± 1.15 yr) : Enlargement of the size of areola 
and increased areolar pigmentation. The nipple and areola form a 
secondary mound above the level of the breast.  
 
Phase V (age: 15.3 ± 1.7 yr) : Final adolescent development of a 
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smooth contour with no projection of the areola and nipple.  
                                             ANATOMY OF  BREAST  
 
 
 
 FIG - Anatomy of the breast. Tangential and cross-sectional (sagittal) views of the 
breast and associated chest wall. 
(Ref: from Romrell et al,15 p 20. Copyright Elsevier) 
 
FIG - Superficial dissection of female breast  
 
Ref: Taken from Moore‘s anatomy text book.  
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The breast: basic structure and function  
―The breasts or mammary glands are highly specialized modified 
sweat glands. The breasts consist of glandular tissue and supporting 
fibrous tissue embedded within fatty tissue matrix, together with blood 
vessels, nerve fibers, and lymphatic vessels. Both males and female have 
breasts: but breasts are normally well developed only in female‖. 
The mammary glands are present in the subcutaneous tissue plane 
overlying the pectoralis major muscle and pectoralis minor muscle. At the 
greatest prominence of the breast is the nipple which is surrounded by a 
circular pigmented area, called the areola. A small portion of the 
mammary gland that extends along infero lateral edge of pectoralis major 
muscle towards the axillary fossa, forming the axillary process or the tail 
of Spence. About sixty percentage of cancer breast  actually originates in 
the axillary tail, that is why it is an important part of clinical breast 
examination. 
11
  
Structure: The breast is formed by of 15-20 lobules of glandular 
tissue surrounded by the fat; the latter responsible for its smooth contour 
and most of the breast bulk. These lobules are separated individually by 
thin fibrous septa running from the subcutaneous tissue to the pectoralis 
fascia  called the suspensory ligaments of Cooper. The breast is tightly 
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attached to the dermis of the skin, especially by substantial skin ligaments 
called (L.retinacula cutis), the suspensory ligaments (of Cooper). These 
suspensory ligaments particularly well developed in the superior part of 
the gland, help support the lobes and lobules of the breast.  
Each lobule is drained by its lactiferous duct  to the nipple, which is 
surrounded by pigmented areola. This areola and nipple are lubricated by 
the    Montgomery‘s glands; which are large, modified sebaceous glands 
that may form sebaceous cysts which may,  become infected.  
 
 
FIG - Sagittal section of the female breast and anterior thoracic wall 
(Ref: Taken from Moore‘s anatomy text book. ) 
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Anatomical extent 
• medially upto Lateral border of sternum to the mid-axillary line 
laterally 
• superiorly from Second to sixth rib inferiorly 
Breast is located between the superficial and deep layers of 
superficial fascia of breast.  Retromammary space is a thin layer of loose 
areolar connective tissue between the deep layer of superficial fascia and 
pectroralis fascia
12
. The breast can develop anywhere along the milk line, 
thus giving rise to accessory breasts or nipples.  
Arterial supply  
  The Perforating branche of  Internal thoracic/mammary artery  
  Lateral branches of Posterior Inter costal arteries 
  Superior thoracic artery 
  Lateral thoracic artery  
  Pectoral branches of thoraco-acromial artery  
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Venous drainage  
―The venous return of the breast has both a superficial and deep 
system. Superficial veins of the breast are located just posterior to the 
superficial layer of the superficial fascia and can be seen by infrared 
photography. Around the nipple these veins form an anastomotic circle - 
the circulus venous”. The deep veins and veins of the superficial plexus 
can be classified into 3 principal groups as follows :  
i) Internal mammary vein  
ii) Tributaries of the axillary vein  
iii) Posterior intercostal veins.  
This system lies in direct continuity with the vertebral plexus of 
FIG - Arterial supply of the mammary gland 
(Ref: Taken from Moore‘s anatomy text book..) 
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veins (Batson's plexus)
13
 that surround the vertebral column extending 
from the base of skull to the sacrum).  
 
Lymphatic Drainage of the Breast : 
Lymph Glands - Three routes for mammary lymphatic drainage 
have been identified:  
I. Axillary Nodes are the most important and receives 75% or more 
of lymphatic flow. These range from 20 to 40 in number and have been 
classified by anatomists by their relationship to axillary structures in 
various groups 14 as follows :  
1. Lateral group also called axillary vein group  
2. External mammary group also called anterior or pectoral group  
3. Posterior or subscapular group  
FIG - Veins of the mammary gland 
(Ref: Taken from Moore‘s anatomy text book.) 
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4. Central group  
5. Apical group  
6. Interpectoral or Rotter's group  
Axillary lymph nodes are divided into three levels according to 
its relation of lymph nodes to the pectoralis minor muscle :  
Level I - Those are located at the lower border of pectoralis minor 
muscle. 
Level II -Lymph nodes that are located deep to the pectoralis minor 
muscle.  
Level III -Lymph nodes along the medial border of pectoralis minor 
muscle.  
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II. Internal Mammary Lymph nodes (around 8-10 nodes) : Lymphatics 
from the medial edge of the breast pierce through the pectoralis major 
muscle and intercostal muscles to drain into the internal mammary lymph 
nodes - located along the sternal border of the internal thoracic trunk. This 
group accounts for 25% or less of lymph flow from the breast. The 
internal thoracic lymph trunks drain into right lymphatic duct or thoracic 
duct. These lymph nodes cannot be palpated, rather they are percussed or 
detected by imaging studies.  
III. Posterior Intercostal lymph nodes - The third route for lymphatic 
FIG - Lymphatic drainage   
(Ref: Taken from Moore‘s anatomy text book..) 
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drainage is via the posterior intercostal lymphatics to posterior intercostal 
lymph nodes where the ribs and vertebrae articulate. There is enough 
evidence that lymphatic drainage from any given region is not limited to 
any one of the foregoing pathways. Nonetheless correlation of patterns of 
lymph node metastasis with the location of primary tumors in the breast 
suggests that preferential pattern of lymphatic flow does exist in the 
breast.  
B. Lymphatic Vessels  
a) There are few channels which drain the overlying skin excluding 
nipple and areola. The integumental lymphatics pass in a fan like radial 
manner and drain into surrounding lymph nodes. Lymphatic trunks from 
skin drain a separate portion and there is no communication between 
adjacent territories.  
 i) From the outer part - terminate at the axillary group of lymph 
nodes.  
 ii) The skin of upper part - drained by vessels which enter into the 
supra-  
  clavicular lymph nodes.  
 iii) The skin over the inner part of gland - drain into internal 
mammary chain of lymph nodes.  
The cutaneous lymphatic channels communicate across the midline with 
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those of opposite breast.  
 
b) Lymphatics of the parenchyma of the breast including nipple & 
areola  
 i) A plexus of lymphatic vessels that lie in the inter-lobular 
connective tissue and freely communicates with a sub areolar lymph 
plexus around the nipple called subareolar plexus of Sappey. The  Efferent 
vessels pass from the breast tissue from the anterior axillary fold to the 
pectoral group of axillary lymph nodes. Some lymph channels may pass 
directly for the sub scapular group of lymph nodes. The Efferent vessels 
drain from the superior part of the breast may drain directly to apical 
group of axillary lymph nodes sometimes may be interrupted by small 
inter-pectoral and infra-clavicular lymph nodes. These lymphatic channels 
run on the deep fascia.  
 ii) Lymphatics from both  medial and lateral part of the breast enters 
into the thorax along the anterior perforating branches of the internal 
thoracic  artery and along the lateral perforating branches of the posterior 
inter-costal vessels. Eventhough most of this lymphatics reaches the 
internal mammary chain a small group of lymphatics may pass to the 
posterior inter-costal lymh nodes lying near the heads of the ribs.  
 iii) Lymphatics from the deep part of the breast pass through the 
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pectoralis major muscle on draining into the axillary or internal mammary 
lymph nodes. 
iv) The plexus of deep fascia consists of fine lymphatic vessels. They do 
not act as a normal pathway for lymphatics from the breast into the 
regional lymph nodes. Fine lymphatics connect the right and left internal 
mammary chains behind the manubrium sterni and small glands may be 
found there.  
 
Lymphatics  from  the nipple, areola & the lobules of the gland 
drains into the sub areolar lymphatic plexus of Sappey. 
From this plexus:  
• Most  lymphatics (>75%),  from lateral  quadrants of breast 
tissue drains to  axillary lymph nodes, first into the anterior/ pectoral 
lymph nodes. However, some lymphatics may drain directly into the other 
axillary group of lymph nodes or even to the inter pectoral rotter‘s nodes, 
delto pectoral nodes, supra clavicular nodes, or the inferior deep cervical 
lymph nodes.  
• Most of  the remaining lymphatics, particularly from  medial 
breast quadrants, drains into  para sternal lymph nodes within 2 cm of the 
latereal sternal border or into the contralateral breast, whereas lymphatics 
from  inferior quadrants of breast may pass deeply into the sub 
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diaphragmatic inferior phrenic lymph nodes in the abdomen. 
 
 
―Lymphatics from  the  breast skin, except the  nipple and areola 
complex drains to  ipsi lateral axillary nodes, inferior deep cervical nodes, 
and  the infra clavicular group of lymph nodes and into para sternal lymph 
nodes of both sides of breast within 2 cm of the lateral border of sternum. 
 
Lymphatics from  the axillary nodes drains into the level III 
clavicular (infra clavicular and supra clavicular) lymph nodes and from 
them into the subclavian lymphatic trunk, which also drains lymphatics 
from the ipsilateral  upper limb. Para sternal nodes drain into 
bronchomediastinal lymphatic trunks.‖ 
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Breast Quadrants :  
 The surface of breast is divided into 4 quadrants for the purpose of 
location 
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FIG - Physiological changes in Breasts 
The breast at different physiologic stages. The central column contains three-
dimensional depictions of microscopic structures. 
A. Adolescence. B. Pregnancy. C. Lactation. D. Senescence 
(Ref: Ref: Taken from Moore‘s anatomy text book. ) 
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Physiological changes in Breasts 
 
―From birth until puberty, there is no difference in the breast tissue 
of both male and female. The breast tissue is made up of connective tissue  
& mammary glands . But physiological changes occur in the female breast 
with puberty, during every menstrual cycle and then pregnancy and 
menopause.  During puberty, increased hormones such as estrogens 
stimulate the secondary sexual  characters, including the development of 
breast parenchyma. The breasts grow in both size and amount of the 
mammary glands & of fatty and connective tissues deposited in the 
breast.‖ 
―In females, with each menstrual cycle hormone fluctuations occur 
which are important forth e developing breast tissues. After every 
ovulation, the female body prepares for pregnancy and thus a change in 
the hormone pattern is noted. One of the purpose of this preparation is to 
stimulate growth of the mammary glands    to make the breast glands 
ready for milk production if  the female became pregnant. The increase in 
size is responsible in  some women to feel breast tenderness during  part 
of their menstrual cycle called cyclical mastalgia, During menstruation, 
the hormone levels drop to low level and the breast glands decrease to 
their normal size.‖  
―During  pregnancy, increased estrogen stimulates breast growth, 
  
  
35 
both increasing the size & number of  glands and the  fatty tissue amount 
in the breasts as part of the body's preparedness for lactation and breast 
feeding. Prolactin & the placental hormones   stimulate milk production 
during pregnancy, but milk secretion is prevented by the high  levels of 
oestrogen & progesterone. But at child birth, the oestrogen and 
progesterone levels drop to very low levels so that milk secretion can 
starting to occur.‖  
―After menopause, the levels of oestrogen levels in the female body 
reduces and the breast tissue is no longer stimulated. Thus, the breast 
content changes from mostly of glands & dense connective tissue to  fatty 
tissue mostly. The dense breast tissue of younger women is responsible for 
difficulty to see through on mammographic study, that is why screening 
mammograms are not ideal in femaels under 40 yrs of age, as masses may 
be missed. 
As the fat content in the breast tissue increases with age, it became 
easier to detect lumps and changes consistent with malignancy on 
mammogram. Branchig of the lactiferous ducts occur in the breast tissues 
during menstruation and pregnancy. Eventhough breast is prepared for 
secretion by mid pregnancy, breasts do not produce milk before the baby 
is born.‖  
―Colostrum is a  yellowish or white colored pre milk fluid, which is 
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secreted from the nipples during the last trimester of pregnancy and during 
initial few days after child birth. Colostrum is especially rich in proteins, 
immune antibodies, and a growth factors acting on the infant's intestines 
for proper development. The elderly female breasts are  small because of 
the decreasing fat content and the atrophic changes of glandular tissue‖. 
RISK FACTORS OF CARCINOMA BREAST 
Etiology  of the cancer breast   remains unknown till. 
Epidemiological  data suggest the well defined factors show an increased 
likelihood of developing the disease. Risk  factors for cancer breast can be 
classified according the following:  
Relative risk <2 Relative risk 2-4 Relative risk >4 
Early Menarche 
breast cancer in a first 
degree relative 
Mutation BRAC1 Or 
BRCA 2 
Late menopause CHEK2 mutation 
Lobular carcinoma in 
situ (LCIS) 
Nulliparity 
Age >35yrs for first 
child birth 
Atypical hyperplasia 
Estrogen plus 
progesterone 
Hormone 
Replacement 
Therapy 
Proliferative breast 
disease 
Radiation exposure 
before 30 yrs age 
Diet and Alcohol use 
Mammographic breast 
density 
 
Post menopausal 
obesity 
  
 TABLE 1- Magnitude of risk for known breast cancer risk factors 
 (Ref: Taken from Devita principles and practice of oncology 10
th
 edition) 
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Risk assessment models : 
Breast cancer risk can be predicted by two risk assessment models 
currently. Gail’s model, which incorporates age at onset of menarche, 
total number of breast biopsies, age at 1
st
 child birth and total number of 
breast cancer in first degree relatives .Gail‘s model is most frequently 
used. It predicts the total cumulative risk of cancer breast  according to 
decade of life.  
The  other frequently used model developed  by Calus and 
colleagues which is based on high penetrance breast cancer susceptibility 
genes. The  Calus model (when Comparing with the Gail model) 
incorporates more information about family history.
 
  
 
  
  
38 
EPIDEMIOLOGY 
―Breast cancer is the most common cancer in the females and is the 
leading cause of death from cancer for women of age group forty to forty 
four years. It totally accounts for about one third of all female cancers and 
is responsible for about one fifth of the cancer related deaths in women.‖  
―Until  1985 Breast cancer was  the leading cause of death, then it 
was crossed by the lung cancer as the leading cause of death. There is a 
ten fold variation in cancer breast  incidence among various countries 
worldwide. England and Wales having the highest age adjusted mortality 
for breast cancer while South Korea having the lowest. Females living in 
less developed countries have a lower incidence of cancer breast 
comparing to women living in well developed countries‖.  
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NATURAL HISTORY OF BREAST CANCER 
 
 
―Natural  history of breast cancer described by Bloom and 
colleagues is based on records of 250  females with untreated cancer 
breast who were treated  on charity hospital wards in Middlesex Hospital, 
London.  
The Primary Breast Cancer: More than eighty percentage show  
fibrosis  involving the stromal  & epithelial tissues of breast. With growth 
of cancer the Cooper's ligaments are shortened and skin dimpling occurs 
which is classic of cancer breast. Localized dermal edema , otherwise 
called peau d orange appearance develops when drainage of lymphatic 
fluid from skin is blocked. With continued growth of cancer cells invading 
the skin and ulceration occurs in upto 75% of untreated cases. Small 
satellite nodules appear near primary ulceration as new areas of skin are 
involved. 
  Locoregional recurrences  occur in general upto 20% of breast 
cancer, among them more than 60% are distant and 20% both loco-
regional and distant.‖  
Axillary lymph node metastases: ―As size of the breast cancer 
increases some cells started to shed into cellular spaces, which are then 
transported via lymphatics to ipsilateral  regional axillary lymph nodes. 
Lymph nodes containing cancer are first soft but later become firm or hard 
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with continued growth. The  nodes adhere each other and form a fixed 
matted mass.‖  
 
―Involvement of Axillary lymph nodes occuring sequentially from the 
level I to central  level II group and then to the apical level III group. 
While distant metastases are responsible for cancer related death in more 
than 95% women , axillary lymph node status is the most important 
prognostic factor correlate for disease free survival in cancer breast . 
About  30% risk of recurrence in node negative women whereas around 
70% risk for node positive women‖ .  
Distant Metastases:  
 The  breast cancers acquire their own blood supply approximately 
twentyth cell doubling time. Thereafter cancer cells shed into  
 systemic veins - pulmonary circulation  lung 
 Axillary and intercostals veins  Batson's plexus of veins vertebral 
columns. Successful implantation of the metastatic foci from cancer breast 
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can occur after the primary cancer size exceeds 0.5cm in diameter. Within 
24 months of treatment  60% of women  develop distant metastases but 
metastases may become evident as late as twenty to thirty years after 
treatment of primary cancer.  
 
  
Distal metastases: 
Bone,  
Lung,  
Pleura,  
Soft tissues and 
 Liver  
Skeletal metastases 
Lumbar vertebra, 
 Femur,  
Thoracic vertebra, 
 Ribs and  
Skull  . 
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HISTOPATHOLOGY OF BREAST CANCER   
 
 
 
 
 
Breast cancer may arise anywhere from the duct system epithelium 
FIG 23- Mammary gland during lactation 
 (Ref: Stain: hematoxylin and eosin, left side, medium magnification 
and right side, high  magnification. Taken from, Eroschenko VP; 
diFiore's Atlas of Histology.) 
 
FIG 22- Nonlactating (inactive) mammary gland 
(Ref: Stain: hematoxylin and eosin,  medium magnification 
left side and right side, high  magnification. Taken from, 
Eroschenko VP; diFiore's Atlas of Histology.) 
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anywhere from the nipple end of major lactiferous ducts upto the terminal 
duct unit in the breast lobule.  
Classification of Primary Breast Cancer:      
Non-invasive Epithelial Cancers :  
• LCIS Lobular carcinoma in situ 
• DCIS Ductal carcinoma in situ   or intra ductal carcinoma  
Invasive Epithelial Cancers :  
• Invasive lobular carcinoma (10-15%)  
• Invasive ductal carcinoma (50-70%)  
• Tubular carcinoma (2-3%)  
• Mucinous or colloid carcinoma (2-3%)  
• Medullary carcinoma (5%)  
• Invasive cribriform (1-3%)  
• Invasive papillary (1-2%)  
• Adenoid cystic and metaplastic carcinoma (2%)  
 Mixed Connective & Epithelial Tumors :  
Cystosarcoma Phyllodes,  
benign and malignant carcinosarcomas and 
 angiosarcomas.  
Non-Invasive Epithelial cancers: Non-invasive neoplasms are 
divided into two: LCIS and DCIS (or Intraductal carcinoma).  
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TABLE 2-   Ductal (DCIS) and Lobular (LCIS) Carcinoma insitu 
of the Breast 
 (Ref: Taken from Devita principles and practice of obcology 10
th
 
edition and Schwartz text book of surgery 9
th
 edition) 
 
TABLE 3- Classification of Breast Ductal Carcinoma in situ (DCIS) 
 (Ref: Taken from Devita principles and practice of obcology 10
th
 edition 
and Schwartz text book of surgery 9
th
 edition) 
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Invasive ductal carcinoma:  
 ―Invasive ductal carcinoma is the most common presentation of 
cancer breast, accounting for fifty to seventy percentage of invasive breast 
cancers in the India. When there is no special features, it is called as 
infiltrating ductal carcinoma nothing otherwise specified (NOS). About 
sixty percentage of cases, IDC-NOS can present with microscopic or 
macroscopic axillary lymph node metastases. IDC-NOS usually presents 
in peri-menopausal or postmenopausal females in the 5
th
  to 6
th
  decades of 
their life as a  firm solitary lump. It has ill defined margins and the cut 
surface will show areas of central stellate configuration with chalky white 
or yellow streaks that are extending to surrounding breast parenchyma. 
Histologically the tumor consists of anaplastic duct lining cells disposed in 
solid nests ,cords, gland masses and mixture of all these. The cells are 
often arranged in small clusters, disseminated in fibrous stroma‖.  
 
FIG 24- Slide showing features of Infiltrating Ductal Carcinoma 
 (Ref:. Taken from, Eroschenko VP; diFiore's Atlas of Histology.) 
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CLINICAL PRESENTATION: 
 ―Breast  cancer can arise from any portion of the  breast, including 
the  axillary tail, it is found most frequently around sixty percentage in 
upper and outer quadrant of the breast which is due to increased amount of 
breast tissue in that particular area. This is followed by the upper inner 
quadrant and retro areolar while lower half of  the breast accounts for the 
rest of occurrence.‖ 
Symptoms caused locally by tumor  
Lump: In about thirty three percentage of breast cancer cases, the woman 
presents with a lump in her breast often when discovered during some 
household activities like bathing. 
Pain: Pain is an uncommon symptom, except for vague pricking 
sensation in the breast pain is often suggestive of a benign condition. If 
present it suggests aggressive type of malignancy.  
Nipple retraction: Usually present in later part of the disease process. 
Recent onset of nipple retraction in an elderly female patient is highly 
suggestive of malignancy.  
Nipple discharge: Present in 3-11% of cases, blood stained discharge 
usually indicates a intraductal carcinoma, Paget's disease or the tumor has 
grown into a major duct.  
Nipple erosion: It is the commonest mode of presentation in Paget's 
disease, also seen in advanced intra ductal carcinomas. Skin involvement 
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which include  peau d'orange, or frank ulceration or skin satellite nodules 
are the signs of locally advanced disease. Fixation  to the chest wall is 
described as cancer-encuirasse. About twenty percentage of breast cancers 
in developing countries present in locally advanced stage.  
Symptoms caused due to metastases :  
Lymphatic spread:  
 Patients may present with swelling in the axilla or supraclavicular 
region, which may be mobile or fixed. Swelling of arm due to lymphatic 
or even venous obstruction in the axilla either due to nodal metastases or 
following radiotherapy or node dissection, is an uncommon but significant 
presentation. 
Hematogenous spread:  
 Respiratory symptoms like cough, breathlessness due to pulmonary 
metastases. Low back pain is a common symptom, caused by secondary 
infiltration and collapse of lumbar vertebrae, with nerve root pains 
radiating to both the legs. A pathological fracture may be the first 
indication of the presence of the disease due to bone metastases.  
       Cerebral metastases may cause a fit or behavioral abnormality. Mass in 
the right upper abdomen, jaundice may be caused due to liver metastases. 
The general symptoms commonly associated with cancer, including malaise, 
weight loss and cachexia, are rare in patients with cancer breast.   
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CLINICAL EXAMINATION : 
 
 
 
 
Examination of breast in 3 positions 
 1. Arms by the side.  
 2. Arms straight up in the air and  
 3. Hands on her hips.  
 
FIG 25- Examination of the breast.  
A. Inspection of the breast with arms at sides. B. Inspection of the breast 
with arms raised. 
C. Palpation of the breast with the patient supine. D. Palpation of the axilla. 
 (Ref: Schwartz text book of surgery 9
th
 edition) 
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INVESTIGATIONS 
Triple assessment: In UK, suspected cases receive triple assessment 
which includes  1) History and physical examination;  
  2) Diagnostic imaging by mammography or Ultrasonography 
and   3) pathological examination - Cytology or histology. 
 Sensitivity ranges from 85% to 95%.
29 
  
 
 
Breast imaging and image guided diagnostic techniques  
 Non-palpable  lesions are frequently diagnosed using Image guided 
breast biopsies . Ultrasonography and mammography assisted techniques 
have been used to a variable extent in different hospitals 
FIG 26- Triple assessment  
 (Ref: Bailey & Love 26
th
 edition) 
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Ultrasonography of breast  
 ―The use of breast ultrasound was first described by Wild and Neal,  
who investigated the usefulness of ultrasound for defining the normal 
breast as well as breast masses. Most procedures are done using hand held 
7.5 MHz to 10 MHz probes with a penetration depth of 4 to 6 cm. Benign 
lesions are characterized by smooth, well-defined margins, homogenous 
internal echo pattern, symmetric posterior  enhancement and 
compressibility. Suspicious lesions show irregular, fuzzy or jagged 
margins, irregular  internal echoes, irregular posterior shadowing and 
show no compressibility.‖ 
Indications :  
• Breast ultrasound can be primarily used to differentiate between solid 
and cystic lesions of breast with an accuracy of 96% to 100%.  
• Ultrasound is the first choice for evaluating mammographically benign 
appearing lesions.  
• Pregnant women having suspicious lesions.  
• Ultrasound is part of evaluation and work up of patients with abnormal 
nipple discharge.  
Ultrasound guided biopsy techniques :  
• Ultrasound guided needle biopsy.  
• Ultrasound guided cyst aspiration- if contents are clear no need for 
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cytological examination.  
• Ultrasound guided FNAC and Core biopsy. 
Ultrasound guided, Vacuum assisted breast biopsy (VAB): Uses the 
handheld VAB device. Less patient discomfort caused by multiple needle 
repositioning.  
• Ultrasound guided, vacuum assisted excisional biopsy: Ensures both 
biopsy specimen as well as complete removal of lesions under ultrasound 
guidance.   
 
 FIG 27- Ultrasound of the breast for a case of carcinoma breast 
showing the lesion in the centre    
(Ref: Bailey & Love 26
th
 edition) 
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MAMMOGRAPHY : 
35,36 
Since 1960s Mammography  has  been  used  in the  North America   
Radiation  dose  of Conventional mammography is  of 0.1 centigray (cGy) 
per study. One  chest x-ray delivers twenty percentage of this dose. 
However there is no increased risk of cancer breast   associated with this 
radiation dose.  
Screening Mammography:  
 It is used to detect unexpected cancer breast  in asymptomatic 
women. craniocaudal (CC) and mediolateral oblique (MLO) are the 
two views of the breast  taken  in screening. Upper Outer quadrant and 
axillary tail is best viewed in the MLO view. Medial aspect of breast is 
best viewed in the CC view provides better visualization   and permits 
greater breast compression.  
FIG 28- Mammogram of the breast for a case of carcinoma breast 
showing the lesion in the centre  
 (Ref: Bailey & Love 26
th
 edition) 
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At present screening mammography should be offered:  
1. Annually to women aged 50 and older.  
2. At least biennially in women aged 40 to 49.  
3. Annually in younger women with significant family history, or a 
history of prior breast cancer or histological risk 
 
Diagnostic Mammography  
 It is used in the diagnosis of women presenting with clinical 
features such as a breast lump, bloody of serous nipple discharge, or an 
abnormality on screening mammography.  It includes magnification and 
compression imaging in addition to MLO and CC views. The additional 
views are 90 
0
 lateral and spot compression views. Compression device 
used here minimizes the motion artifact, improves the picture definition, 
separates overlying  breast tissues and decreases the  amount of radiation 
dose. Magnification (x1.5) improves better visualization of margins.  
 
Diagnostic mammography may be offered to:  
1. Evaluate the  opposite breast.  
2. To evaluate the questionable or ill defined mass or other suspicious 
changes in breast.  
3. To search for any occult cancer in patients with positive nodal status.  
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4. When women is undergoing conservative breast surgery to detect 
concomitant lesion in the same breast.  
Mammographic abnormalities suggestive of malignancy can be divided 
into:  
• Density abnormalities-masses, architectural distortion and asymmetries.  
• Micro calcifications-The presence of fine, stippled, clustered calcium in 
and around a suspicious breast lesion is highly suggestive of malignant 
breast lesion, especially in younger women.  
 
Breast biopsy techniques 
1. Fine needle aspiration cytology:   
 “Fine needle aspiration of a palpable breast lump is easily 
performed in an out-patient setting as a painless procedure. A 1.5 inch, 22 
or 23 guage needle attached to a 10 ml syringe is commonly used. The 
surgeon performing the procedure to control the syringe using a syringe 
holder with one hand while positioning the breast lump with the opposite 
hand. After placing the needle inside the lump, suction is applied while the 
needle is moved back and forth with the lump for six passes‖.  
 ―The cellular material expressed inside the needle hub is put onto 
microscope slide. Both air-dried and ethanol or cytofix used for fixing 
microscopy slides  for analysis. The sensitivity and specificity approaches 
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100% when the breast mass is clinically or mammographically suspicious. 
The false negative rate is 5% and false positive rate is 2%. 
Disadvantages  
a. Cannot differentiate between in situ and invasive cancer.  
b. No histological detail is obtained as compared to a tissue biopsy.  
c. False negative results are high due to sampling errors.  
d. Requires expert and specialized pathological interpretation‖ 
 
2. Core biopsy:  
 ―Core biopsy can be performed on palpable breast masses with a 14 
gauge needle. A variety of techniques instruments can be used to provide 
a core or tissue such as manual biopsy needle or automated biopsy guns 
which has replaced FNAC in many departments. This technique is 
performed under local anaesthesia. Tissue specimens from the biopsy guns 
are placed in formalin and then processed to paraffin blocks for analysis. 
The only disadvantage is because of sampling errors.  
Advantages :  
a. Produces excellent histological detail rather than cytological specimen.  
b. In situ cancers can be differentiated from infiltraive cancers.  
c. Grading of tumors is possible.  
d. Identification of estrogen receptors is also possible‖.  
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3. Open surgical biopsy:  
 ―Biopsy is required when FNAC or core biopsies have failed to 
demonstrate malignant disease in a clinically suspicious lumps. It has the 
disadvantage of  hospital admission, even majority of patients can be 
treated and  discharged the same day. Main  advantage of this is that it 
provides a definitive method  of proving or excluding malignant breast 
disease. Open surgical excision biopsy can occasionally be done under 
local anesthesia but more easily under general anesthesia‖ 
 
4. Open surgical biopsy and frozen section:  
―This procedure can be done at the time of definitive surgery. But this is 
outdated. Modern surgical practice should avoid the outdated approach of 
performing mastectomy on the basis of frozen section.  
5. Incisional biopsy: For cases presenting with an ulcer or lump >4 cm 
size, this method was used. Not used routinely and has been replaced by 
FNAC‖.  
 
6. Breast imaging and image guided diagnostic techniques 
 Non-palpable  lesions are usually diagnosed using Image guided 
breast biopsies. Ultrasonography and mammography assisted techniques 
have been used to a variable extent in different hospitals.  
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Mammography assisted biopsy techniques : 
1. Needle Localization Breast Biopsy:  
 Until 1990, this was the only method to evaluate  non-palpable 
Mammographic  abnormality,  which included surgical excision of 
breast masses marked with preoperative wire localization 
 
2. Large core needle biopsy (LCNB):   
 ―It can be either performed under ultrasound or mammographic 
guidance. Mammographic calcifications are sampled using stereotactic 
capabilities. Histological detail can be obtained. Stereotactic LCNB 
involves the patient lying prone on core biopsy table with breast in 
compression. computer analysis of triangulated mammographic images 
helps a robotic arm and automated biopsy gun to take specimen.‖ 
 
Other investigations 
Xeroradiography These techniques are semilar to those of 
mammography but the exception that it provides a positive image rather 
than a negative one, which allows easy interpretation, good visualization. 
It requires less irradiation and is carried out in lighted rooms.  
Ductography: The primary indication is nipple discharge, when the 
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discharge fluid is blood stained. Contrast media is injected into one or 
more major lactifrerous ducts and CC and MLO mammography views are 
obtained. Intraductal papillomas appear as small filling defects, but 
malignant lesions appear as irregular masses or as multiple filling defects. 
Ductal lavage and cytology using microcatheters is used in women with 
increased breast cancer risk.  
Thermography: Malignant lesions are hotter than normal and benign 
lesions due to increased vascularity and increased metabolism. It has 85% 
diagnostic accuracy.  
Magnetic Resonance Imaging:   MRI can be used to screen the breasts 
of high-risk women especially younger women and of women with a 
newly diagnosed cancer breast.
 
1. It can be useful to differentiate scar due to previous surgery from 
recurrence in females who have had previous breast conservation therapy.  
2. Gold standard investigation for imaging breasts of females with 
implants.  
3. useful in screening of pregnant female breast 
Investigations to assess the metastases  
• Liver function tests: Enzyme levels may be elevated in hepatic  
metastases.  
• Serum calcium: elevated in patients with bony metastases.  
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• Chest X-ray: Features suggestive of secondaries include coin 
lesions, interstitial infiltration, mediastinal widening, pleural effusion and 
rib secondaries.   
• Bone X-rays: Usually present with osteolytic lesions while some 
lesions are rarely osteogenic.  
• Bone Scan: Technetium Tc99 labeled bone scans are more sensitive 
than X-rays. They are most helpful when strong suspicion of skeletal 
metastases is present.  
• Ultrasound scan of abdomen is used to asses liver metastases, 
lymph nodes, free fluid in abdomen, ovarian secondaries or any pelvic 
deposits.  
 
HORMONE RECEPTORS 
 
 ―The laboratory discovery and subsequent measurement of estrogen 
receptors (ERs) and progestin receptors (PRs) in breast tumors have given 
the physician useful tools to aid in the treatment of women with breast 
cancer. The ER and PR belong to a large class of nuclear receptor 
proteins, are present in normal breast, and other tissues and are expressed 
in up to 60% to 70% of breast cancers. In both normal and tumor cells, 
estrogen binds to the ER, which is a large protein molecule located in the 
cytoplasmic and nuclear fractions of the cell. The receptor hormone 
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complex results in gene activation and transcription of mRNA and cell 
proliferation.‖  
 ―The blockade of estrogen inhibits protein translocation, cell 
proliferation, and leads to initiation of cell death. One method of reducing 
estrogen levels is with direct blockade of ER with drugs like tamoxifen. 
Synthesis of progestin receptors is a product of estrogen action on cells, it 
is an estrogen dependent process. Hormone receptors can be routinely 
identified by a variety of immunohistochemical staining of  the breast 
tissue. Specimen may be obtained by core cut needle biopsy, open biopsy 
or postoperative specimen of breast tissue‖.  
 Hormonal therapy should be recommended to patients whose breast 
cancer contains ER or PR, regardless of age, menopausal status or 
involvement of axillary nodes. Benefit of hormonal therapy in receptor 
negative tumors is very less.  
Estrogen receptor Progesterone receptor 
Response % to 
hormonal therapy 
+ + 78 
+ - 34 
- + 45 
- - 10 
 
 
  
TABLE 4- Response rate to hormonal therapy 
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Methods of Measurement of steroid Receptors :  
1. Titration method : Where the sample is incubated with increasing 
amounts of labelled steroid with and without the presence of unlabelled 
inhibitor.  
2. Biochemical assays :  
 a. Dextran coated charcoal (DCC) method first described by 
Korenman and Dukes in 1970.45  
 b. Sucrose density gradient analysis.  
 c. High performance liquid chromatography.  
3. Immunoflourescence : Flourescein labelled steroid is bound to tissue 
steroid receptors. Amount of bound steroid is visualized by fluorescent 
microscopy.  
4. Enzyme linked immunoassays : Sandwich assay with immobilized 
monoclonal antibody to receptor.  
5. Immunohistochemistry (IHC) : Monoclonal antibody specific to 
steroid receptor binds to tissue steroid receptor. Second Ab labeled with 
peroxidase is used to localize first Ab binding, visualization of receptor in 
tissue with substrates in peroxidase stain. 
6. Cloning of steroid receptor genes and generation of specific 
complementary DNA and hybridization analysis of the generated 
complementary DNA.  
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7. In-situ hybridization of hormone receptor mRNA levels in 
histological sections. 
 
HER-2/neu oncoprotein 
 ―The 185 KD oncoprotein HER-2/neu is a mimicker of the tyrosine 
kinase receptor family,which is a type of growth factor receptor with fifty 
% homology to the epidermal growth factor receptor EGFR, and has 
surface membrane, transmembrane, and cytoplasmic domains. The 
cytoplasmic domain to which antibodies for immunohistochemical studies 
have been derived that has activating phosphorylation and transcription 
initiating functions, The activating ligand for the HER-2 receptor is 
unknown. 
 Since the initial reports describing the association of HER-2 
amplification with poor clinical outcome, the gene product has been the 
subject of at least 48 prognostic research studies involving 15,000 patients 
with cancer breast‖. 
The techniques used to evaluate HER-2/neu status in breast cancer  
  Gene-based assays such as southern and slot blotting,  
  PCR- Polymerase chain reaction methods, and  
  more recently in-situ hybridization featuring both 
flouorescent and nonfluorescent techniques - FISH 
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 Qualitative and quantitative measurements of HER-2/neu protein 
have been performed by IHC on frozen and archival tissues, western 
blotting and enzyme immunoassays (ELISA). 
 
BIOMARKERS 
 ―Breast cancer biomarkers are of several types.. These include 
BRCA-1, BRCA-2 and other germline mutations. Exposure biomarkers 
include measurement of carcinogen exposure.   Biomarkers are biologic 
alterations in breast tissues that occur between initiation and cancer 
development. These biomarkers are used  in short term chemoprevention 
trials, include histologic changes and indices of proliferation. Drug effect 
biomarkers (serum glutathione reductase activity, ornithine decarboxylase 
activity) are used to monitor biochemical effect of drugs‖.  
  Prognostic and predictive biomarkers in cancer breast  include: 
1. Indices of proliferation: such as Proliferating cell nuclear antigen 
(PCNA), a nuclear protein, which is over expressed in tumor with high 
mitotic index, high histologic grade.  
2. Indices of apoptosis: Bcl-2 family proteins appear to inhibit apoptosis. 
The death signal protein bax induced by the growth factor deprivation. 
The bax:bcl- 2 ratio represent intracellular regulatory mechanism with 
prognostic implications.  
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3. Indices of angiogenesis:  vascular endothelial growth factor (VEGF) 
and angiogenesis index.  
4. Growth factor receptors and growth factors: Such as Human 
epidermal growth factor  (HER)-2/neu  and epidermal growth factor 
receptor (EGFr). Over expression is associated with receptor negative, p53 
positive tumors. Anti HER2/neu therapy is now an important breast cancer 
therapy.  
5. p53 overexpression  correlates  with  high  histologic  grade of 
tumor, high proliferative fraction, aneuploidy, HER2/neu overexpression 
and ER/PR negative tumors.  
IMMUNOHISTOCHEMISTRY 
 ―Immunohistochemistry is one of the powerful ancillary methods 
used in pathology today which has revolutionized the study of disease and 
its prognosis. The most profound method today has been of 
Immunohistochemistry (IHC) – which is a powerful and cost effective tool 
applicable in light microscopy. IHC is an aesthetic component to the 
practice of histology, which validates the morphologic judgements 
pathologists make‖.  
 ―Immunohistochemistry (IHC), also called as 
immunocytochemistry, is a method for localizing specific antigens in body 
tissues or cells based on antigen-antibody recognition or reaction; IHC 
  
  
65 
seeks to exploit the specificity provided by the binding of an Ab with its 
Ag at a light microscopic level.
‖
  
VIRTUES OF IHC :  
• It works in routine (less than ideal) conditions.  
• It is compatible with standard fixation and embedding procedures.  
• Studied under light microscope.  
• Permanent slides can be prepared which can be stored.  
• It can be performed retrospectively on archival material.  
• It is sensitive and specific and is applicable to almost any 
immunologic molecule.  
• It is interpreted in morphologic context.  
• It does not require fluorescent microscope.  
MAIN USES OF IHC :  
• Classifying undifferentiated tumors, lymphomas, neuroendocrine 
and soft tissue tumors.  
• Detection & accurate assay of the tumor biologic factors of 
predictive  & prognostic  values such as hormone receptors (ER, PR) and 
HER-2/neu in breast cancer.  
• Detection of metastatic tumor cells in bone marrow, lymphnodes & 
serous fluids when the cell groups are too less or confusing.  
• Additionally, immune histochemistry is being increasingly used in 
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the characterization of the underlying agent in many infectious diseases 
applying specific antibodies to  bacterial, viral or fungal antigens like  in 
HIV,HCV,HSV,HPV,TB bacilli and leprabacilli.  
 The validity of immunohistochemistry in diagnostic histopathology 
depends on the quality of immunostains used. In addition to antibody 
quality,3 other factors have a major impact on immunohistochemistry.  
1. Tissue fixation and processing.  
2. Unmasking of epitopes.  
   3. Sensitivity of the detection system.  
 Formaldehyde is the most popular fixative used in great part because of 
its low cost, easy of preparation, & because it preserves morphologic 
details with few artifacts. However, formaldehyde fixation results in a 
variably reversible loss of immune reactivity by its masking or damaging 
some antibody binding sites.  
The different methods of detection are:  
Enzyme bridge technique: hardly used these days  
PAP (peroxidase anti-peroxidase) method devised by Sternberger et al 
in 1970  
Biotin avidin procedure devised by Heitzman and Richards in 1974  
Avidin-Biotin Conjugate procedure (ABC) This procedure improved 
sensitivity was devised by Hsu et al.  
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Biotin streptavidin system (B-SA)  
Alkaline phosphatase and anti-alkaline phosphatase method 
(APAAP) of Cordell et al  
Protein A method is not much in use.  
EnVision systems  
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TNM STAGING OF CARCINOMA BREAST 
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TNM STAGE GROUPING – CARCINOMA
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TREATMENT OF BREAST CANCER 
Once diagnosed of caner breast , the type of treatment offered to a patient 
is determined by  clinical stage of the disease. But before any therapy is 
started, the doctor must discuss the plan of treatment and all the 
complications with the patient and the attenders.  
In Situ Breast Cancer (Stage 0) 
Lobular carcinoma in situ (LCIS):  
The current treatment protocol is either observation alone with or without 
hormonal therapy using Tamoxifen. The goal of the treatment is to prevent 
or detect at an early stage the invasive cancer that  develops  subsequently 
in 25% to 35% of females.  
Ductal carcinoma in situ (DCIS): 
 Total Mastectomy is done for women with DCIS and evidence of 
extensive disease while Lumpectomy and radiation therapy is done for 
women with limited disease. Lumpectomy alone is enough for women 
with lesion less than 0.5 cm.  
Early Invasive Breast Cancer (Stage I, IIa, or IIb): 
Currently,  
a. MRM - Mastectomy with axillary lymph node dissection or 
b. Breast conservation BCS (lumpectomy with assessment of axillary 
lymph node status and radiation therapy) are considered gold standard for 
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treatment of early cancer - stages I and II of breast cancer.  
Indications of Total Mastectomy in early Breast Cancer : 
- When Tumour is more than 4 cms  
- Multicentric tumour  
- Poorly differentiated tumour  
-Tumour margin is not clear of tumour after breast conservation surgery 
 Axillary lymphadenopathy or metastatic disease in SLN sentinel 
lymph node necessitates an axillary lymph node dissection. Traditionally 
axillary clearance is done upto level II in early stage breast cancers. If the 
SLN sentinel lymph node cannot be identified or is found to harbor 
metastatic disease, then  axillary lymph node dissection is performed. 
Systemic therapy for early stage breast cancer  
Adjuvant chemotherapy:  
i.  Considered for all node positive breast cancers.  
ii.  Cancers size larger than 1cm .  
iii.  Node negative cancers -  size more than 0.5 cm in  with adverse 
prognostic features  such ass vessel invasion, high nuclear grade, high 
histologic grade, with negative harmone status and HER2/neu over 
expression. 
Tamoxifen therapy: Considered for hormone receptor positive (ER/PR) 
females with cancers larger than 1 cm in size.  
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Radiation therapy: All conservative breast surgeries need radiation to 
chest wall. If lymph node status is N0 then no radiation to axilla is needed. 
If N1 and less than 3 nodes are positive, no radiation to axilla is given 
(plus axillary dissection). If N1 and more than 3 nodes radiation is 
mandatory to axilla (plus axillary dissection).  
 
MASTECTOMY: 
Implies to surgical removal of entire breast parenchyma 
Skin sparing mastectomy (SSM): Includes the resection of  the 
nipple/areola complex including existing biopsy scar, and removal of 
whole breast parenchyma. If indicated a sentinel lymph node biopsy or 
axillary can also be performed. The types of incisions can be used are 1. 
periareolar, 2.tennis racquet,3. reduction mammoplasty and 4.modified 
elliptical.
41
  
 
 
FIG 29- Types of skin sparing mastectomy 
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Advantages: Minimal skin is harvested, thus generous skin envelope 
remains after mastectomy, thus cosmetic results are excellent. It affords 
improved symmetry with the other breast when compared with traditional 
modified radical mastectomy. Can be done in early breast cancers but 
contraindicated in inflammatory carcinoma, locally advanced cancers and 
multifocal disease. There is a recurrence rate of less than two percentage 
when Skin Spaing Mastectomy is used for T1 to T3 cancers.  
 
Simple mastectomy: A simple or total mastectomy removes all of the  
breast tissue, the nipple areola complex, and the skin. A transverse 
elliptical incision is taken on either sides of the breast and mastectomy is 
performed.
  
 
Extended simple mastectomy :  Removes all of the breast tissue, the 
nipple-areola complex, skin, and the level one and level two axillary 
lymph nodes. 
 
Radical Mastectomy:  
   William Stewart Halsted and Meyer descried radical mastectomy 
in 1894, which removes all of the  breast tissue & skin, the nipple-areola 
complex, the pectoralis major muscle and pectoralis minor muscles and 
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the level one, two and three axillary lymph nodes. Preservation of the 
axillary vein, cephalic vein and long thoracic nerve of Bell was made.  
Good loco regional control is obtained  in this procedure. But it is no 
longer indicated as it causes excessive morbidity with no increased 
survival benefit. The word radical is not completely true as it ignores 
internal mammary chain of lymph.
 
 
Modified Radical Mastectomy:  
 Patey's Modified radical mastectomy (MRM) preserves both the 
pectoralis major and pect minor muscles, allowing removal of the level 
one and level two axillary nodes but not level three or apical lymph nodes.  
 
 
 
FIG 30- Modified Radical mastectomy 
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Operative Procedure  
Anesthesia: This procedure is performed under General Anesthesia.  
Access:  
Place the patient in supine position, with arm on operating side extended 
on an arm board.  
Prepare the skin and place towels to allow access to breast and axilla. 
With skin marking pen draw a transverse elliptical incision (Stewart's)  
and encompass approximately 5cm of skin around the lesion and also the  
nipple.  
Ensure that you will be able to approximate the wound edges after 
surgery.  
Elevate the skin flaps in the plane between subcutaneous fat and breast 
tissue.  
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PROCEDURE 
―Ensure the flaps (7-8mm) are not too thin, no breast tissue is left behind. 
Raise the upper flap to the upper limit of breast tissue that is 2-3 cm below 
lower border of clavicle. Raise the lower flap to the lower limit of breast, 
upto infra-mammary fold. Dissect down until pectoralis fascia is reached, 
introduce a finger covered by a swab and find a submammary plane 
between the fascia and the breast. Proceed dissection in this plane, the 
anatomical boundaries are the anterior border of the latissimus dorsi 
muscle laterally; to  the midline of the sternum medially; superiorly the 
subclavius muscle & the caudal extension of the breast two to three cm 
inferior to the inframammary fold inferiorly. Preservation of the medial 
pectoral nerve is made in this procedure.‖  
Axillary dissection: 
 ―The axillary lymph nodes are removed as a part of modified radical 
mastectomy. The axilla is opened by an incision in axillary fascia, the 
most lateral limit of the axillary vein is identified and the areolar tissue of 
the lateral axillary space is lifted as the vein is cleared on its anterior and 
inferior surfaces. The cephalic vein should be preserved as it is an 
important collateral if main axillary vein is injured. Using combination of 
sharp and blunt dissection lateral border of pectoralis major and anterior 
border of latissimus dorsi are identified; these landmarks form limits of 
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axillary dissection. The level I nodes at the junction of axillary vein and 
anterior border of latissimus dorsi are cleared. For level II nodes pectoralis 
minor beneath pectoralis major is pulled out and retracted forwards and 
medially. 
If level III clearance is desired, both borders of pectoralis minor should 
be defined and divided at its insertion to coracoid process. The 
thoracodorsal bundle, the long thoracic nerve is preserved.. Finally the 
whole breast and the axillary contents are removed from the surgical bed  
as en masse and sent for pathologic assessment after labelling the margins. 
Then the wound is closed in two layers with a closed system suction 
drainage.‖ 
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Locally advanced breast cancer (Stage IIIa or IIIb): 
Stage IIIa with operable disease:  Auchincloss MRM - Modified 
radical mastectomy followed by adjuvant CT chemotherapy followed by 
adjuvant RT radiation therapy. Chemotherapy is used to maximize the 
distant disease free survival while radiation therapy is used to maximize 
locoregional contol and  disease free survival. Neoadjuvant chemotherapy 
can be given in selected cases of IIIa cancers to reduce the size of the 
tumor. 
Stage IIIa (inoperable) and IIIb:  Neoadjuvant chemotherapy plus 
Modified radical mastectomy plus  adjuvant chemotherapy plus adjuvant 
radiation therapy.  
 
 
FIG 30- Steps of Modified Radical mastectomy 
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Distant metastases (Stage IV):  
It is the blood spread of cancer into bones, lungs, pleura, liver, soft 
tissues,  
brain and adrenals. Breast lump is evaluated by FNAC/ incision biopsy, 
chest CT, LFT, USG abdomen, CT abdomen, whole body scanning, CT 
brain, and tissue study for ER/PR/Her- 2 neu receptor status for starting 
chemotherapy  
Treatment options :  
To improve quality of life  
To relieve pain of secondaries like bone, lungs  
To relieve neurological problems like convulsions, space occupying 
cranial problems  
Other symptomatic relief  
 
Treatment strategies in metastatic carcinoma of the breast includes :  
1. Chemotherapy : CMF, CAF, Taxanes in combination.  
2. High dose of CT using cyclophosphamide, cisplatin, carmustine, 
melphalan.  
3. Haemopoetic growth factor - enhance cell kill with less bone marrow 
toxicity.  
4. Radiotherapy - used in bone metastasis, brain secondaries  
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BREAST CANCER PROGNOSIS  
 Five year survival rate for breast cancer in  
  stage one I  94%.  
  stage IIa  85%  
  stage IIb  70- 52%,   
  stage IIIb  48%; and  
  stage IV  18%.  
 
PREVENTION OF BREAST CANCER  
―Prevention is always better than cure. Hence based on the concept that 
detecting and treating small cancers and precancerous lesions could save 
lives, breast screening and more recently chemoprevention of breast 
cancer in high-risk groups have been started to reduce the mortality‖. The 
three commonly used screening methods are:  
1. Breast self examination 
2. Clinical breast examination 
3. Screening Mammography 
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MATERIALS AND METHODS  
PLACE OF STUDY:  
 Rajiv Gandhi Government General Hospital and Madras Medical 
College, Chennai.   
TYPE OF STUDY:  
   prospective randomized control trial. 
PERIOD OF STUDY:  
  March 2016  to September  2016.  
INCLUSION CRITERIA:    
 All patients admitted in RGGGH with  
1.Age>18 yrs 
2.Female  Patients 
3.Primary breast cancer 
EXCLUSION CRITERIA:   
• Previous axillary surgery(<4 months) 
• Diabetic patients 
• Recent steroid treatment(<1 month) 
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• Pregnancy  
• Immunosuppression  
SAMPLE SIZE:  
  70 cases; control group:35, Test group:35 
METHODOLOGY  
 This will be a hospital based time bound study. All those cases which 
satisfy the inclusion criteria will be included in this study. All patients 
will be taken into the study after obtaining written informed consent. 
They will be subjected to baseline investigations (CBC, LFT, RFT, blood 
grouping and typing) and specific investigations namely  ultrasound 
breast. Data will be collected in the form of detailed history, clinical 
examination and investigations (radiological investigations), intra 
operative findings and ultimate outcome of the patients.  
ASSESSMENT OF PARAMETERS:  
• 24 hr seroma volume.  
• Age 
• Intraoperative findings. • Postoperative outcome.  
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· Total cases  70  
· No. of patients in control group  35 
· No. of patients in study group  35 
The study group were given inj methyl prednisolone 80mg locally into the 
wound cavity for first two days after surgery and the other group had a 
normal dressing. 
24hr seroma collection in the DT was measured both in study and control 
groups for 1 week till DT removal and it was compared between these two 
groups. 
  
 
    
35 35 
Total patients 
control group Test group
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RESULTS 
AGE DISTRIBUTION  
AGE GROUP  
(YRS)  
No of patients 
30-35 _ 
36-40 4 
                          41-45  5 
46-50  15 
51-55  10 
56-60  18 
>60  18 
Majority of the patients belong to older age group, early  with the highest 
being in the age group 56-60 followed by >60 age group. So breast 
cancer is most common ib older age group patients.  
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MEAN VOLUME OF SEROMA 
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ii) IIIrd POD: 
 
  
 
iii) VII POD: 
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PERCENTAGE REDUCTION IN SEROMA 
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MEAN SEROMA VOLUME IN OBESE PATIENTS 
 
MEAN SEROMA VOLUME IN OLDER PATIENTS 
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DISCUSSION  
―Breast cancer is one of the most common malignancy in women. 
Surgery is the mainstay treatment. Modified radical mastectomy with or 
without reconstruction or breast preservation in addition to axillary node 
dissection are common surgical procedures in breast cancer‖. 
           ―Most common complication after breast cancer surgery is wound 
seroma.The exact etiology of seroma formation is controversial. several 
interventions have been reported with the aim of reducing seroma 
formation including fibrin glue,fibrin sealant,bovine thrombin application 
and altering surgical technique to close dead space.However,it has been 
suggested that although the use of these interventions might reduce the 
risk of seroma formation ,further studies are needed to verify the real 
impact on long term morbidity of such techniques.‖ 
―Several studies have been performed to investigate factors related to post 
surgical seroma.These studies have observed that the early removal of 
drains might led to increased incidence of seroma whereas others have 
shown that drains removal time  had no influence on seroma formation‖. 
            ―The findings from our study also indicated that the length of time 
drains are left did not influence the seroma rate. Similar observation was 
reported by a recent study where the use of drains did not prevent seroma 
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formation on the other hand it is associated with along postoperative 
hospital stay and more pain after surgery for breast cancer.compression 
dressing to prevent seroma rate is a common method used by many 
surgeons.A study demonstrated that use of pressure garments to reduve 
postoperative drainage after axillary lymph node dissection for breast 
cancer is not warranted. However we think that the use of pressure 
garments and prolonged limitation of arm activity not only reduces 
seroma formation but also may increase the incidence of seroma 
formation after removal of drain and even might cause shoulder 
dysfunction.‖ 
―A seroma survey  failed to identify any significant independent risk 
factors for seroma formation. Obesity, Modified radical mastectomy and 
a large drainage volume during the first three postoperative days were 
associated with an increased risk, although these findings were not 
significant. None of the following could be identified as risk factors: 
duration of drainage, hormone receptor status, immobilization of the 
shoulder,  nodal status or lymph node metastases, number of lymph nodes 
removed, number of drains, previous biopsy, type of drainage, use of 
fibrin sealant. Other authors have found that obesity, age, hypertension, 
and the use of electrosurgery predispose to seroma formation.‖  
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           ―The mechanism behind the formation of a seroma is not known in 
detail. It was concluded that a seroma was not just an accumulation of 
serum, but probably formed part of the postoperative inflammatory 
response involved in wound healing. Steroids inhibit the inflammatory 
response through inhibition of cytokine function. An increased 
complication rate after surgery in patients treated with a single dose of 
glucocorticoid has not been demonstrated‖ 
     In the study group, it was tested whether a single dose of 
glucocorticoid (methylprednisolone) given locally inside the wound 
cavity on day of surgery and day 1 postoperatively  was effective against 
seroma formation after mastectomy and axillary dissection. The drainage 
volume during the first two postoperative days, total seroma volume 
during days 1-7  were reduced, but not significantly.  There were no 
differences in wound healing time or rate of infectious complications 
between the groups . The temporary immunosuppression induced by 
postoperative glucocorticoid infusion  may, theoretically, be a risk factor 
in this study. In general, the same factors that stimulate wound healing 
also stimulate malignant cell growth. Inflammation stimulates the 
production of cytokines, as do tumour cells.  It is estimated that steroids 
probably do not stimulate, but may have an inhibitory effect on the 
growth of unrecognized micro-metastases left by cancer surgery. 
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CONCLUSION  
The results of this study suggest that, 
1. Seroma formation is one of the important post operative 
complication after MRM 
2. More common in patients who undergo MRM 
3. Highest incidence is among older age groups and obese patients. 
4. Local injection of methyl prednisolone 80mg into the wound cavity 
significantly has some prophylactic effects against seroma formation 
in post MRM patients. 
5. During this study there is no adverse reactions in patients by 
injection of methyl prednisolone. 
6. The use of inj methyl prednisolone ,as indeed of every new 
therapeutic modality ,should not be practiced alone but be 
incorporated in a holistic strategic approach. 
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ABBREVIATIONS 
 
 
 
MRM                      Modified radical mastectomy 
 
 
LCIS                       Lobular  carcinoma insitu 
 
 
DCIS                       Ductal carcinoma insitu 
 
 
BCS                         Breast conserving surgery 
 
 
FNAC                      Fine needle aspiration cytology 
 
 
ER /PR                    Estrogen/Progesterone receptor 
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PATIENT PROFORMA  
                                DATA COLLECTION SHEET 
1.Patient particulars: 
Name:            Age:     Sex:   
IP No. :              Address: 
DOA:     DOS:         DOD:              Occupation: 
2.Diagnosis: 
3.Chief complaints(with duration) 
A.lump        B.pain/ discharge       C.other complaints     
PAST HISTORY: 
PERSONAL HISTORY: 
EXAMINATION: 
INVESTIGATIONS: 
MANAGEMENT: 
COURSE DURING THE STUDY 
24hr Seroma volume 
Day1 Day2 Day3 Day 4 Day5 Day6 Day7  
        
COMORBIDITIES: 
CONDITION ON DISCHARGE 
FOLLOWUP: 
 Case details of  Test group: 
S.NO NAME 
AGE/ 
SEX 
PROCEDURE  
DONE STAGE WEIGHT DT DRAIN  (ML) 
 
      
DAY 1 DAY 2 DAY 3  DAY 4  DAY 5 DAY 6  DAY 7 
 
1 SHANTHI 65/F MRM T2N1M0 55KG 100 ml 75ml 70ml 50ml 50ml 30ml <30ml 
 
2 LAKSHMI 56/F MRM T2N1M0 52KG 110ml 80 ml 80ml 70 ml 50ml 30ml <30ml 
 
3 PARVATHY 54/F MRM T2N1M0 58KG 70ml 70ml 50ml 50ml 30ml 30ml <20ml 
 
4 SAVITHRI 47/F MRM T2N1M0 49KG 75ml 70ml 50ml 50ml 50ml 30ml 30ml 
 
5 KASIAMMAL 56/F MRM T2N1M0 60KG 200ml 150ml 120ml 100ml 75ml 70ml 50ml 
 
6 VANAJA 58/F MRM T2N1M0 62KG 150ml 100ml 70ml 50ml 50ml 30ml 30ml 
 
7 KALYANI 46/F MRM T2N1M0 48KG 100ml 70ml 70ml 60ml 50ml 30ml <30ml 
 8 CHITHRA 38/F MRM T2N1M0 55KG 80ml 75ml 50ml 50ml 30ml <20ml DT removed 
 
9 KAVERI 48/F MRM T2N1M0 64KG 120ml 100ml 100ml 70ml 70ml 50ml 30ml 
 
10 LEELAVATHY 49/F MRM T2N1M0 53KG 150ml 100ml 100ml 70ml 50ml 50ml 30ml 
 
11 KUPPAMMAL 50/F MRM T2N1M0 58KG 100ml 70ml 70ml 50ml 30ml <30ml <30ml 
 
12 MAYAVATHY 51/F MRM T2N1M0 68KG 160ml 120ml 100ml 80ml 70ml 50ml 50ml 
 
13 RAJALAKSHMI 61/F MRM T2N1M0 51KG 110ml 80ml 70ml 70ml 50ml 30ml 30ml 
 
14 BHAVANI 42/F MRM T2N1M0 58KG 80ml 75ml 50ml 40ml 30ml <30ml 20ml 
 
15 SIVAGAMI 53/F MRM T2N1M0 70KG 150ml 100ml 70ml 50ml 50ml 30ml <30ml 
 
16 MUNIAMMAL 58/F MRM T2N1M0 66KG 100ml 80ml 75ml 50ml 50ml 30ml <30ml 
 
17 GANGESHWARI 64/F MRM T2N1M0 69KG 110ml 90ml 70ml 50ml 50ml 30ml 30ml 
 
18 SAROJA 57/F MRM T2N1M0 57KG 100ml 70ml 50ml 50ml 30ml 30ml <30ml 
 
19 THANGAMMAL 70/F MRM T2N1M0 54KG 75ml 60ml 50ml 50ml 30ml <20ml DT removed 
 
20 VIJAYA 47/F MRM T2N1M0 71KG 100ml 80ml 70ml 50ml 50ml 30ml <30ml 
 
21 KURUVAMMAL 56/F MRM T2N1M0 60KG 90ml 75ml 75ml 50 ml 30ml 30ml <20ml 
 
22 CHELLATHAI 68/F MRM T2N1M0 50KG 80ml 50ml 50ml 30ml 30ml <20ml DT removed 
 
23 GOWRI 45/F MRM T2N1M0 65KG 100ml 90ml 75ml 60ml 50ml 50ml 30ml 
 
  
  
17 
S.NO NAME 
AGE/ 
SEX 
PROCEDURE  
DONE STAGE WEIGHT DT DRAIN  (ML) 
 
24 LOGAMMAL 66/F MRM T2N1M0 68KG 100ml 90ml 80ml 50ml 50ml 30ml <30ml 
 
25 MALLIGA 59/F MRM T2N1M0 74KG 110ml 100ml 70ml 70ml 50ml 40ml 40ml 
 
26 KAMALA 58/F MRM T2N1M0 62KG 120ml 100ml 100ml 70ml 50ml 50ml 30ml 
 
27 JEGATHAMBAL 47/F MRM T2N1M0 67KG 200ml 150ml 120ml 100ml 70ml 50ml 50ml 
 
28 GIRIJA 53/F MRM T2N1M0 62KG 120ml 100ml 75ml 60ml 50ml 50ml 30ml 
 
29 JEYANTHI  64/F MRM T2N1M0 59KG 150ml 100ml 80ml 60ml 50ml 30ml <20ml 
 
30 RAJESHWARI 51/F MRM T2N1M0 55KG 110ml 100ml 80ml 60ml 50ml 50ml 30ml 
 
31 MYTHILI 46/F MRM T2N1M0 66KG 100ml 80ml 60ml 50ml  50ml 30ml 30ml 
 
32 KANIMOZHI 52/F MRM T2N1M0 49KG 90ml 60ml 60ml 50ml 30ml <30ml <20ml 
 
33 MALA 36/F MRM T2N1M0 58KG 75ml 70ml 50ml 30ml 30ml <30ml DT removed 
 
              
34 VANAJA 63/F MRM T2N1M0 56KG 150ml 120ml 100ml 80ml 50ml 50ml 30ml 
 
35 NITHYA 44/F MRM T2N1M0 60KG 100ml 80ml 50ml 50ml 30ml 30ml <20ml 
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Case details of control group: 
 
NAME        AGE/SEX PROCEDURE STAGE WEIGHT DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 DAY6 DAY 7 
 
1 SHANTHA 59/F MRM T2N1M0 58kg 170ml 150ml 150ml 130ml 120ml 100ml 80ml 
 
2 PRABAVATHY 46/F MRM T2N1M0 56kg 190ml 160ml 150ml 150ml 130ml 110ml 100ml 
 
3 VIDHYA 39/F MRM T2N1M0 49kg 150ml 150ml 130ml 120ml 100ml 80ml 50ml 
 
4 JOTHI 56/F MRM T2N1M0 60kg 180ml 170ml 150ml 120ml 120ml 100ml 70ml 
 
5 CHELLAMMAL 64/F MRM T2N1M0 57kg 200ml 180ml 160ml 140ml 120ml 100ml 100ml 
 
6 AMUDHA 58/F MRM T2N1M0 48kg 120ml 100ml 100ml 90ml 70ml 50ml 30ml 
 
7 UMA 49/F MRM T2N1M0 53kg 160ml 150ml 120ml 100ml 100ml 70ml 50ml 
 
8 GANGAIYAMMAL 65/F MRM T2N1M0 59kg 140ml 120ml 100ml 100ml 90ml 70ml 70ml 
 
9 VALLIYAMMAL 64/F MRM T2N1M0 56kg 160ml 150ml 150ml 130ml 100ml 100ml 90ml 
 
10 THENANDAAL 61/F MRM T2N1M0 50kg 170ml 150ml 150ml 130ml 120ml 100ml 80ml 
 
11 THAMARAI 58/F MRM T2N1M0 65kg 160ml 150ml 140ml 140ml 130ml 120ml 100ml 
 
12 ROJA 43/F MRM T2N1M0 63kg 200ml 190ml 170ml 150ml 130ml 100ml 100ml 
 
13 AYESHA 53/F MRM T2N1M0 55kg 120ml 120ml 100ml 90ml 80ml 50ml 30ml 
 
14 SASIKALA 46/F MRM T2N1M0 59kg 150ml 150ml 100ml 100ml 90ml 80ml 60ml 
 
15 AMBIKA 54/F MRM T2N1M0 55kg 170ml 160ml 160ml 150ml 130ml 130ml 110ml 
 
16 RANI 41/F MRM T2N1M0 55kg 120ml 120ml 100ml 80ml 70ml 50ml 30ml 
 
17 SORNAM 59/F MRM T2N1M0 51kg 220ml 200ml 200ml 180ml 150ml 150ml 120ml 
 
18 MATHI 56/F MRM T2N1M0 62kg 250ml 220ml 200ml 190ml 170ml 150ml 130ml 
 
19 MALAR 47/F MRM T2N1M0 66kg 220ml 200ml 200ml 190ml 160ml 150ml 150ml 
 
20 ANNAPOORNI 66/F MRM T2N1M0 54kg 170ml 160ml 160ml 150ml 120ml 100ml 80ml 
 
21 ARUNA 52/F MRM T2N1M0 62kg 140ml 150ml 120ml 100ml 100ml 80ml 60ml 
 
22 CHANDRIKA 59/F MRM T2N1M0 58kg 200ml 180ml 170ml 140ml 120ml 100ml 80ml 
 
23 CHARULATHA 57/F MRM T2N1M0 66kg 190ml 180ml 150ml 150ml 160ml 150ml 120ml 
 
  
  
19 
 
NAME        AGE/SEX PROCEDURE STAGE WEIGHT DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 DAY6 DAY 7 
 
24 FATHIMA BEGUM 69/F MRM T2N1M0 57kg 170ml 150ml 150ml 130ml 120ml 110ml 100ml 
 
25 LAKSHMI 48/F MRM T2N1M0 59kg 160ml 150ml 150ml 140ml 130ml 100ml 70ml 
 
26 MANJULA 52/F MRM T2N1M0 49kg 140ml 120ml 110ml 90ml 70ml 50ml 30ml 
 
27 PADMINI 49/F MRM T2N1M0 52kg 130ml 130ml 110ml 100ml 100ml 75ml 50ml 
 
28 SAROJAMMAL 70/F MRM T2N1M0 55kg 250ml 220ml 180ml 180ml 150ml 130ml 120ml 
 
29 NIRMALA 58/F MRM T2N1M0 56kg 220ml 200ml 180ml 170ml 140ml 120ml 100ml 
 
30 VALLIYAMMAI 69/F MRM T2N1M0 60kg 200ml 200ml 170ml 150ml 140ml 120ml 90ml 
 
31 PAULINE 37/F MRM T2N1M0 51kg 180ml 160ml 150ml 150ml 120ml 100ml 80ml 
 
32 GEETHA 50/F MRM T2N1M0 55kg 160ml 140ml 140ml 110ml 80ml 60ml 40ml 
 
33 KARMEGAKUZHALI 64/F MRM T2N1M0 56kg 260ml 220ml 200ml 160ml 150ml 150ml 120ml 
 
34 BHAVANI 55/F MRM T2N1M0 71kg 170ml 150ml 150ml 140ml 120ml 100ml 100ml 
 35 RAJESHWARI 65/F MRM T2N1M0 58kg 190ml 170ml 170ml 150ml 120ml 100ml 80ml 
  

 
